Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort studyOleksandr Korotych, Askar Yedilbayev, Nana Kiria et al.|The Lancet Infectious Diseases|2024Cited by 23
Culture conversion at six months in patients receiving bedaquiline- and delamanid-containing regimens for the treatment of multidrug-resistant tuberculosisShynar M. Maretbayeva, A Issayeva, Michael Rich et al.|International Journal of Infectious Diseases|2021Cited by 14